CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Cut Costs with In-House R&D Laboratory
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently submitted a Health Canada research application for a license that will permit in-house research in its new Kelowna-based research and development (“R&D”) laboratory. Construction of the new lab, which will be located within Lexaria’s new head office, is anticipated to be completed by the end of January 2019. A recent article further discussing LXRP reads, “Having the work done in-house will help expand the work schedule and reduce costs and development timelines. The company is currently recruiting new staff as it prepares for an increase in…